Study Guide for Clinical (General and Radiation Oncology)
Last verified on September 7, 2023
Download this study guide in printable .pdf format
This exam is designed to assess your understanding of the entire field of oncology and radiation oncology. Included are questions on the following topics related to cancer and cancer therapies of every type, as well as appropriate benign entities:
- Epidemiology and pathology
- Normal and pathologic anatomy
- Elements of cancer diagnosis, staging, treatment (including the utilization of modalities other than radiation), and follow-up
- Tumor markers for diagnosis and follow-up
- Natural history and routes of local, regional, and distant spread
- Selection of treatment modality (specific details of multimodality therapies including sequencing, interactions, and specific agents)
- Management of both local and metastatic disease
- Optimum radiation simulation, field design, and radiation techniques (including external beam, radiosurgery, brachytherapy employing HDR and LDR sources, and unsealed radioactive agents) for various clinical situations
- Tumor localization and respiratory management
- Radiation target and organs at risk dose distribution
- Selection of optimum radiation volume, dose, and fractionation
- Radiation dose constraints
- Interpreting a dose-volume histogram
- Understanding of how radiation affects normal tissues
- Side effects of radiation and other modalities, and how to manage them
- Evidence-based treatment results (e.g., with surgery, radiation therapy, chemotherapy, biological therapy, or other emerging interventions)
- Patterns of failure
- Palliative care
- Precision and errors in treatment planning
- Quality assurance
- Patient and personnel safety
- Bioethics
- Biostatistics
Pediatrics/Pediatric CNS Tumors | 5% to 9% |
Gastrointestinal (GI) Tract | 10% to 14% |
Gynecology | 8% to 12% |
Genitourinary (GU) Tract | 10% to 14% |
Lymphomas and Leukemias | 6% to 10% |
Head, Neck, and Skin | 8% to 12% |
Lung/Mediastinum | 10% to 14% |
Breast | 10% to 14% |
Soft Tissue/Bone | 3% to 7% |
Central Nervous System (CNS) | 6% to 10% |
Non-Clinical Skills | 2% to 5% |
Pediatrics
- Retinoblastoma
- Wilms tumor
- Neuroblastoma
- Rhabdomyosarcoma
- Lymphomas
- Leukemias
- Histocytosis X
- Ewing sarcoma and other bone and cartilage tumors
- Pediatric solid tumors
- Soft-tissue sarcoma
- Germ cell tumor
- Hepatic tumor
- Osteosarcoma
- Hodgkin lymphoma
- Medulloblastoma
- Astrocytoma (glioma), low grade
- Astrocytoma, high grade
- Brain stem glioma
- Ependymoma
- Pineal/germ cell
- Craniopharyngioma
- Optic tract
- Esophagus
- Stomach
- Small bowel
- Colon/rectum
- Anus
- Pancreas
- Biliary tract
- Liver
- Cervix
- Endometrium/uterus
- Ovaries and fallopian tubes
- Vagina/urethra
- Vulva
- Prostate
- Bladder
- Testes
- Kidneys
- Ureter
- Urethra
- Penis
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Leukemia, chronic and acute
- Multiple myeloma/plasmacytoma
- NK/T cell lymphoma
- Cutaneous lymphomas
- Lips
- Larynx
- Oral cavity
- Oropharynx
- Hypopharynx
- Nasopharynx
- Salivary glands (major and minor)
- Orbits/eye
- Thyroid gland
- Paranasal sinuses
- Skin (basal, squamous, melanoma, and Merkel)
- Non-small cell
- Small cell
- Superior sulcus tumor
- Thymomas, thymic, and/or other mediastinal tumors
- Mesothelial/pleural tumors
- Early-stage
- Locally advanced
- Inflammatory
- Carcinoma in situ
- Locally recurrent
- Metastatic carcinoma
- Soft tissue sarcomas
- Ewing sarcoma
- Desmoid tumor
- Osteosarcoma and/or chondrosarcoma
- Other benign and malignant bone and joint tumors
- Astrocytoma, low grade
- Astrocytoma, high grade
- Medulloblastoma
- Brainstem glioma
- Ependymoma and ependymoblastoma
- Pineal
- Lymphoma
- Optic tract glioma
- Oligodendroglioma
- Meningioma (benign and malignant)
- Pituitary
- Spinal cord
- Craniopharyngioma
- Arteriovenous malformation (AVM)
- Acoustic neuroma
- Consent in the impaired patient
- HIPAA issues
- Research issues
- General consideration
- Human factors related to error
- Communication of error
- Frequency/necessity of repeat calculations
- General considerations
- P value and significance
- Risk ratio
- True positive/negative
- Meta-analysis
- General considerations
- Routine vs exceptional QA
- QA after linac service
- Value of peer review
- Root cause analysis
- General considerations